INTRODUCTION
============

Reactive oxygen species (ROS) are generated during many cellular processes including catalysis and energy production ([@b2-molcell-37-3-226-6]; [@b30-molcell-37-3-226-6]). In addition, abruptly over-produced ROS cause DNA damage, lipid peroxidation, cell death, and many pathological disorders such as inflammation, ischemia, diabetes, and Parkinson's disease (PD) ([@b20-molcell-37-3-226-6]). However, defense systems in cells remove excessively produced ROS and maintain the cellular balance of ROS ([@b20-molcell-37-3-226-6]). PD, a neurodegenerative disease, is characterized by a progressive loss of dopaminergic (DA) neurons in the substantia nigra (SN) and an accumulation of Lewy bodies ([@b4-molcell-37-3-226-6]; [@b5-molcell-37-3-226-6]). DA neurons are associated with motor functions and loss of these neurons in PD patients could cause typical symptoms such as tremor, bradykinesia, rigidity, and akinesia ([@b19-molcell-37-3-226-6]).

Sensitive to apoptosis gene (SAG), a member of the zinc RING finger protein family, is found in both the cytoplasm and nucleus of the cell ([@b3-molcell-37-3-226-6]). SAG can bind to metal ions, zinc or copper, and thereby protect cells from metal ion-induced apoptosis ([@b6-molcell-37-3-226-6]; [@b22-molcell-37-3-226-6]). SAG overexpressed in U937 cells prevents ionizing radiation-induced apoptosis through inhibiting ROS production ([@b16-molcell-37-3-226-6]). It has been suggested that SAG can attenuate ischemia-induced brain injury *in vivo* mouse models ([@b27-molcell-37-3-226-6]) and in gerbil ischemia/reperfusion models ([@b3-molcell-37-3-226-6]; [@b15-molcell-37-3-226-6]; [@b29-molcell-37-3-226-6]). In addition, SAG overexpression promotes cell growth under serum starvation by mediating p27 ubiquitination and degradation ([@b7-molcell-37-3-226-6]). Elevated levels of SAG have been found in human colon carcinomas and transfection of antisense SAG into the tumor cells reduced growth of these cells ([@b10-molcell-37-3-226-6]).

Although many peptides and proteins have remarkable therapeutic potential, their low permeability and poor bioavailability have been obstacles in the process of developing them as drugs. Several useful strategies have been suggested to improve the delivery of proteins into various cells or tissues ([@b21-molcell-37-3-226-6]; [@b25-molcell-37-3-226-6]). Particularly, protein transduction domains (PTD) including Tat and PEP-1 have the ability to efficiently cross the blood brain barrier (BBB) and cellular membranes. Therefore, exogenous proteins can be efficiently delivered to viable tissues and cells through fusion with PTD ([@b1-molcell-37-3-226-6]; [@b18-molcell-37-3-226-6]; [@b21-molcell-37-3-226-6]; [@b25-molcell-37-3-226-6]).

In this study, we investigated whether Tat-SAG fusion protein could be effectively delivered to SH-SY5Y neuroblastoma cells and brain tissues and so prevent 1-methyl-4-phenylpyridinium (MPP^+^)-induced apoptosis in SH-SY5Y cells, and protect DA neurons in the SN in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD model. Therefore, we suggest that Tat-SAG may be a useful agent for treatment of ROS-related diseases including PD.

MATERIALS AND METHODS
=====================

Materials and cell culture
--------------------------

Restriction endonuclease and T4 DNA ligase were purchased from Promega (USA). Plasmid pET-15b and *Escherichia coli* strain BL21 (DE3) were obtained from Novagen (Germany). Oligonucleotides were synthesized from Bioneer (Korea). An Ni^2+^-nitrilotriacetic acid Sepharose Superflow column was purchased from Qiagen (USA). Fetal bovine serum (FBS) and antibiotics were purchased from Gibco BRL (USA). MPTP was dissolved in saline and intraperitoneally (i.p.) injected. All other chemicals and reagents, unless otherwise stated, were obtained from Sigma-Aldrich (USA) and were of the highest analytical grade available.

Animals
-------

Male C57BL/6 mice (8-week-old, Hallym University Experimental Animal Center, Korea) were used. They were housed at an ambient temperature of 23°C under a 12 h light /12 h dark cycle and were provided with food and water *ad libitum*. All experimental procedures involving animals and their care conformed to the Guide for the Care and Use of Laboratory Animals of the National Veterinary Research & Quarantine Service of Korea and were approved by the Hallym Medical Center Institutional Animal Care and Use Committee.

Preparation of Tat-SAG and SAG proteins and their transduction into SH-SY5Y cells
---------------------------------------------------------------------------------

Expression vectors of Tat-SAG and SAG were constructed and two proteins were overexpressed and purified as described previously ([@b15-molcell-37-3-226-6]). To assess the dose- and time-dependency of SAG and Tat-SAG transduction into SH-SY5Y cells, cells were plated into 6-well plates and were cultured in EMEM for 24 h. Cells were incubated with SAG and Tat-SAG in serum-free medium for 60 min. Then cells were harvested by trypsinization for 10 min and washed with phosphate-buffered saline (PBS) three times. The cells were lysed with a lysis buffer and Western blot analysis was performed. To evaluate the intracellular stability of Tat-SAG, cells were exposed to Tat-SAG (3 μM) for 60 min, and harvested at designated times (1--60 h). The levels of Tat-SAG were analyzed by Western blot analysis using an His antibody and a horseradish peroxidase-conjugated secondary antibody.

Cell viability measurement
--------------------------

An MTT assay was performed as described previously ([@b17-molcell-37-3-226-6]). SH-SY5Y cells were seeded into 96 well plates at the density of 10,000 cells/well overnight. The cells were treated with SAG or Tat-SAG in serum-free EMEM medium 1 h prior to incubation with MPP^+^ (4.0 mM). After 18 h incubation, MTT was added to each well for 4 h and the formazan crystal was dissolved in DMSO. Optical density was measured at 590 nm using an ELISA plate reader.

ROS generation
--------------

ROS generation was assessed by determining fluorescence intensity derived from a process converting 2′,7′-dichlorofluorescein diacetate (DCF-DA) into fluorescent DCF. SH-SY5Y cells were plated into 96 well plates and pretreated with or without SAG and Tat-SAG for 60 min. This was followed by incubation with MPP^+^ (4.0 mM) for 30 min and staining with DCF-DA (20 μM) for 30 min. The fluorescence was detected using a fluorescence microscope (Nikon, Japan) at 485 nm excitation and 538 nm emission.

Western blot analysis
---------------------

Tissue samples were homogenized using a microtube homogenizer and cells were lysed in a lysis buffer. The protein concentrations in cell lysates or tissue homogenates were determined using a protein assay kit. Equal amounts of protein samples were resolved by 15% sodium dodecyl sulfate-polyacryl-amide gel electrophoresis (SDS-PAGE) and then electrotransferred to a nitrocellulose membrane. The membrane was blocked with 5% non-fat dry milk in TBS-T buffer (25 mM Tris-HCl, 140 mM NaCl, 0.1% Tween 20, pH 7.5) and was incubated with a primary and secondary antibody. The membrane was developed with enhanced chemiluminescence reagents according to the manufacturer's instructions (USA). The β-actin level in each sample was used as a loading control. The band densities were analyzed by image analysis software.

Confocal fluorescence microscopy
--------------------------------

After transduction of SAG and Tat-SAG into SH-SY5Y cells, their intracellular distributions were assessed by confocal fluorescence microscopy. Cells were grown on glass coverslips and exposed to SAG and Tat-SAG (3 μM) for 60 min. The cells were washed with PBS three times and fixed with 4% paraformaldehyde at room temperature for 10 min, followed by incubation with an anti-histidine antibody and Alexa fluor 488-conjugated secondary antibody (Invitrogen, USA). 4′6-diamidino-2-phenylindole (DAPI) was used for nuclear counterstaining. The fluorescence image was analyzed using an Olympus FV-300 confocal fluorescence microscope.

Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay
-----------------------------------------------------------------------------------

To assess the effects of SAG or Tat-SAG on MPP^+^-induced DNA fragmentation, SH-SY5Y cells were pre-incubated with Tat, SAG, and Tat-SAG for 1 h, followed by treatment with MPP^+^ (4.0 mM) for an additional 18 h. TUNEL staining was performed using a Cell Death Detection kit (Roche Applied Science, Switzerland) according to the manufacturer's instructions.

*In vivo* transduction of Tat fusion protein
--------------------------------------------

To assess whether SAG and Tat-SAG proteins would traverse the BBB, SAG and Tat-SAG (3 mg/kg body weight) were i.p. injected into the mice (n = 7 mice/group). The mice were sacrificed 12 h later. The distribution of SAG and Tat-SAG in the SN were evaluated by histological analysis using a rabbit anti-histidine polyclonal antibody and biotinylated goat anti-rabbit secondary antibody.

Protein treatment in MPTP-induced PD animal model
-------------------------------------------------

Mice were divided into 5 groups as follows; control, MPTP, MPTP + SAG, MPTP + Tat, and MPTP + Tat-SAG (n = 7 mice/group). Saline, SAG, Tat, and Tat-SAG (3 mg/kg body weight) were i.p. administered to mice and then MPTP (20 mg/kg body weight) were injected four times at 2 h intervals the following day. The mice were sacrificed 7 days after MPTP treatment. Animals were anesthestized by an i.p. injection with sodium pentobarbital (100 mg/kg body weight) and fixed transcardially with 4% paraformaldehyde. The brains were post-fixed in the same fixative for 4 h, frozen and sectioned. Staining of tissue sections was carried out as previously described ([@b14-molcell-37-3-226-6]). Sections were blocked by 3% bovine serum albumin in PBS for 30 min and were probed with primary antibodies \[His and tyrosine hydroxylase (TH)\] and a biotinylated secondary antibody. Also, cresyl violet staining was performed to detect viable cells after TH immunostaining. The sections were visualized with 3,3′-diaminobenzidine (DAB) in 0.1 M Tris buffer and mounted on gelatin-coated slide. Images were captured and analyzed using an Olympus DP72 digital camera. The sections were processed and analyzed by an observer who was blinded with regard to mouse groups.

Behavior test
-------------

To assess the motor functions of mice, a Rotarod test was performed using Rotarod, Series 8 (IITC, USA) as described previously ([@b11-molcell-37-3-226-6]). The acceleration of rotation gradually increased from 0 to 45 rpm. Each mouse was placed on the rotarod. The distance (m) and time (s) that each mouse spent on the rotarod without falling were automatically recorded.

Statistics
----------

Data are expressed as the means ± SD. Comparison between groups was performed by Student's *t*-test. Values of *P* \< 0.05, *P* \< 0.01, *P* \< 0.005, and *P* \< 0.001 were considered to be statistically significant.

RESULTS
=======

Tat-SAG transduced into SH-SY5Y cells in a time- and dose-dependent manner
--------------------------------------------------------------------------

Expression vectors of SAG and Tat-SAG, a SAG protein fused with a Tat peptide, were constructed and their schematic structures were shown in [Fig. 1A](#f1-molcell-37-3-226-6){ref-type="fig"}. Two proteins were purified as described previously ([@b15-molcell-37-3-226-6]) and their purities were confirmed by SDS-PAGE and Western blot analysis ([Figs. 1B](#f1-molcell-37-3-226-6){ref-type="fig"} and [1C](#f1-molcell-37-3-226-6){ref-type="fig"}).

We first examined the abilities of SAG and Tat-SAG to penetrate into SH-SY5Y cells. SH-SY5Y cells were exposed to SAG and Tat-SAG (0.5--3.0 μM) for 60 min and the transduced protein levels in the cells were measured by Western blot analysis using an anti-His antibody. As shown in [Fig. 2A](#f2-molcell-37-3-226-6){ref-type="fig"}, Tat-SAG levels increased in a time-dependent manner, compared to the level of SAG, which was not detected in the cells. In addition, Tat-SAG transduced into the cells in a time-dependent manner as observed when treated with Tat-SAG (3.0 μM) for various incubation times (10--60 min) ([Fig. 2B](#f2-molcell-37-3-226-6){ref-type="fig"}). Immunofluorescence data revealed that Tat-SAG was significantly detected in the nucleus as well as cytoplasm of SH-SY5Y cells ([Fig. 2C](#f2-molcell-37-3-226-6){ref-type="fig"}). We next evaluated the stability of Tat-SAG protein after its transduction into SH-SY5Y cells. Western blot analysis showed that the Tat-SAG level at 48 h was reduced to 24% of the initial level (1 h after transduction) ([Fig. 2D](#f2-molcell-37-3-226-6){ref-type="fig"}). A significant level of Tat-SAG was observed in SH-SY5Y cells for 1--60 h after its transduction. These results suggest that Tat-SAG effectively transduced into SH-SY5Y cells and further, that the intracellular Tat-SAG level was significantly maintained for 48 h.

Transduced Tat-SAG inhibits ROS production and cell death
---------------------------------------------------------

SAG is known to scavenge ROS induced by redox agents ([@b6-molcell-37-3-226-6]). To confirm whether Tat-SAG would inhibit ROS generation, SH-SY5Y cells were treated with MPP^+^ (4.0 mM) 30 min after exposure to SAG, Tat, or Tat-SAG for 60 min. SAG and Tat failed to suppress ROS generation caused by MPP^+^. In contrast, an obvious decrease in the fluorescent signal was observed in the MPP^+^ + Tat-SAG treated sample ([Fig. 3A](#f3-molcell-37-3-226-6){ref-type="fig"}). Next we assessed whether Tat-SAG could inhibit MPP^+^-induced toxicity in SH-SY5Y cells using an MTT assay. The MTT assay showed that, when treated only with SAG or Tat-SAG, neither SAG nor Tat-SAG affected the proliferation of SH-SY5Y cells. However, when treated with MPP^+^, Tat-SAG (0.1--0.5 μM) significantly suppressed MPP^+^-induced toxicity in a dose-dependent manner ([Fig. 3B](#f3-molcell-37-3-226-6){ref-type="fig"}). These results demonstrate that Tat-SAG significantly inhibited ROS production in response to MPP^+^ and this was associated with suppression of MPP^+^-induced toxicity.

Tat-SAG protects SH-SY5Y neuroblastoma cells by inhibiting DNA fragmentation and apoptosis induced by MPP^+^
------------------------------------------------------------------------------------------------------------

SAG overexpression is known to protect cells from apoptosis through scavenging ROS and inhibiting caspase activation ([@b6-molcell-37-3-226-6]). To examine whether Tat-SAG suppresses DNA fragmentation caused by exposure to MPP^+^, a TUNEL assay was carried out after SH-SY5Y cells were treated with MPP^+^ following transduction of SAG and Tat-SAG for 1 h. Transduction of Tat-SAG remarkably decreased the number of TUNEL labeled cells in contrast with the SAG and Tat treated samples ([Fig. 4A](#f4-molcell-37-3-226-6){ref-type="fig"}). The percentage of fluorescently labeled cells in the Tat-SAG-treated sample was reduced to approximately 55%, compared with the MPP^+^-treated sample ([Fig. 4B](#f4-molcell-37-3-226-6){ref-type="fig"}). Further, we investigated whether Tat-SAG could affect MPP^+^-triggered apoptosis progression in SH-SY5Y cells. Tat-SAG markedly suppressed elevated levels of cleaved caspase-3 and bax, apoptotic markers, and also significantly up-regulated reduced levels of bcl-2, an anti-apoptotic marker ([Figs. 4C](#f4-molcell-37-3-226-6){ref-type="fig"} and [4D](#f4-molcell-37-3-226-6){ref-type="fig"}). These findings demonstrate that transduced Tat-SAG inhibits MPP^+^-induced DNA fragmentation and apoptosis in SH-SY5Y cells, possibly by protecting SH-SY5Y neuroblastoma cells from oxidative stress caused by MPP^+^.

Transduced Tat-SAG protects dopaminergic neurons in the SN from MPTP, a neurotoxin
----------------------------------------------------------------------------------

We next evaluated the ability of Tat-SAG to efficiently cross the BBB as well as to enter SH-SY5Y cells. SAG and Tat-SAG were i.p. injected into mice (3 mg/kg body weight, n = 7 mice/group) and mice brains were harvested 12 h later. Brain tissues were sectioned and stained using anti-histidine and biotinylated secondary antibodies. As shown in [Fig. 5A](#f5-molcell-37-3-226-6){ref-type="fig"}, histological analysis showed that transduced Tat-SAG proteins were found in the, predominantly, cytoplasm as well as nucleus of DA neurons in the brain parenchyma, indicating that Tat-SAG has the capability to cross the BBB, in contrast with SAG.

It has been shown that MPTP is converted to MPP^+^ in glial cells and subsequently MPP^+^ induces the death of DA neurons in the SN. We examined whether Tat-SAG can protect DA neurons in the SN against MPTP toxicity in a MPTP-induced PD mouse model. Mice (n = 7 mice/group) were i.p. injected with SAG and Tat-SAG (3 mg/kg body weight) and the next day MPTP (20 mg/kg body weight) was i.p. injected 4 times. The mice in the Tat-SAG group had significantly more TH positive cells in the SN, although less than the control mice, when compared to the MPTP-treated sample (Left panels, [Fig. 5B](#f5-molcell-37-3-226-6){ref-type="fig"}). Furthermore, to confirm the survival of DA neurons in the SN of the mice after MPTP treatment, brain tissues were double-stained using a TH antibody and cresyl violet. Cresyl violet staining showed that MPTP treatment significantly induced the death of DA neurons in the SN. As expected, a significant number of viable TH neurons were seen in the Tat-SAG-treated sample (Right panels, [Fig. 5B](#f5-molcell-37-3-226-6){ref-type="fig"}). The quantification data of TH positive cells shows that Tat-SAG protects TH positive neurons from MPTP ([Fig. 5C](#f5-molcell-37-3-226-6){ref-type="fig"}). Next, to assess the effect of Tat-SAG on the motor functions in the MPTP-treated mice, we measured the distance and time that mice could stay on a moving rotarod without falling. The Tat-SAG-treated group spent significantly more time and moved longer distances on a rod, although less and shorter than the control group, compared to the MPTP, SAG, and Tat treated groups ([Figs. 5D](#f5-molcell-37-3-226-6){ref-type="fig"} and [5E](#f5-molcell-37-3-226-6){ref-type="fig"}). Therefore, the results demonstrate that Tat-SAG represses the death of DA neurons in the SN caused by MPTP, thereby leading to a decrease in impairment of motor functions.

DISCUSSION
==========

Neurodegenerative diseases, including Alzheimer's disease, Huntington's disease, and Parkinson's disease, are different from each other in terms of their causes and symptoms as well as the affected area of the brain ([@b4-molcell-37-3-226-6]; [@b5-molcell-37-3-226-6]; [@b19-molcell-37-3-226-6]; [@b20-molcell-37-3-226-6]). However, excessive ROS generation seems to be tightly related to these neurodegenerative diseases. Mitochondria produce ROS and also neutralize ROS *via* the functions of various defense systems, which they possess, such as glutathione, glutathione peroxidase, superoxide dismutase, and NADPH ([@b20-molcell-37-3-226-6]). Therefore, it has been suggested that, if antioxidant molecules are up-regulated in target tissues or cells susceptible to oxidative damage, they may prevent oxidative stress and subsequent cell death. We produced PTD-fused proteins, including PEP-1-rpS3 and Tat-ANX, using PTD tools in order to increase therapeutic proteins and peptides in any cell type and tissues. These proteins, including PEP-1-rpS3 and Tat-ANX, can be efficiently delivered to cells and animal tissues, and they can inhibit ROS-related diseases involving inflammation and ischemic insult in animal models ([@b1-molcell-37-3-226-6]; [@b18-molcell-37-3-226-6]).

SAG, also known as RBX2/ROC2, a protein that is a component of the Skp1-Cullin1-F-box-protein E3 ubiqutin ligase ([@b24-molcell-37-3-226-6]; [@b26-molcell-37-3-226-6]), was identified as a redox-inducible antioxidant protein ([@b6-molcell-37-3-226-6]; [@b22-molcell-37-3-226-6]) and is induced by various stimuli, including redox agents, ischemia/reoxygenation, hypoxia, neurotoxin, heat shock, and UV irradiation ([@b26-molcell-37-3-226-6]). Human SAG protein possesses the binding sites for a lot of transcription factors, such as NF-κB, c-MYC, AP-1 and p53, and also it can bind to zinc and copper metal ions, which can induce apoptosis ([@b6-molcell-37-3-226-6]; [@b12-molcell-37-3-226-6]). Numerous studies have shown that SAG functions as an antioxidant or anti-apoptotic protein. For example, SAG knockdown in human prostate cancer PC3 using siRNA, increased the susceptibility to inducers of ROS production or apoptosis, such as actinomycin D and etoposide ([@b28-molcell-37-3-226-6]). It is known that in multiple human tumor tissues, overexpression of SAG lead to reduced levels and half life of NOXA, a pro-apoptotic member of the Bcl-2 family. Also, SAG knockdown in cancer cells could sensitize the cells to radiation and induce apoptosis through accumulation of NOXA ([@b12-molcell-37-3-226-6]). SAG-overexpressing SH-SY5Y cells inhibited MPP^+^-induced neurotoxicity by down-regulation of ROS generation and c-Jun N-terminal kinase 1 activity ([@b13-molcell-37-3-226-6]). SAG overexpression in mouse epidermal cells promotes ultra-violet B-induced skin hyperplasia, but not skin tumors ([@b9-molcell-37-3-226-6]). In addition, SAG suppresses TPA-induced neoplastic transformation *via* ubiquitination and degradation of c-Jun ([@b8-molcell-37-3-226-6]) and protects cells from apoptosis by promoting the ubiquitination and degradation of procaspase-3 ([@b23-molcell-37-3-226-6]). Thus, these reports suggested that an increased level of SAG could enhance survival of various cells.

As is well-known, in the intrinsic apoptotic pathway various apoptosis inducers, including ROS, induce the loss of mitochondrial membrane potential and release of pro-apoptotic proteins, such as Bax, into the cytosol. Consequently, it leads to activation of caspases and DNA fragmentation, a hallmarker of apoptosis. Consistent with other previous studies, we demonstrated that Tat-SAG significantly suppresses signaling of apoptosis including ROS generation ([Fig. 3A](#f3-molcell-37-3-226-6){ref-type="fig"}), release of Bax, and activation of caspase-3 ([Figs. 4C](#f4-molcell-37-3-226-6){ref-type="fig"} and [4D](#f4-molcell-37-3-226-6){ref-type="fig"}), thereby leading to suppression of DNA fragmentation ([Figs. 4A](#f4-molcell-37-3-226-6){ref-type="fig"} and [4B](#f4-molcell-37-3-226-6){ref-type="fig"}) and cell death ([Fig. 3B](#f3-molcell-37-3-226-6){ref-type="fig"}). Chanalaris et al. reported that SAG is found in both the cytoplasm and nucleus of rat cardiomyocytes ([@b3-molcell-37-3-226-6]). Their findings were consistent with our results which showed that Tat-SAG was localized in the cytoplasm and nucleus of SH-SY5Y cells, although different from the cell line used in their studies. However, until now it was not evident that either Tat-SAG in the cytoplasm or nucleus can predominantly prevent MPP^+^-induced apoptosis or otherwise what role the transduced Tat-SAG can play in the nucleus of SH-SY5Y cells. Therefore, additional studies were required to clearly reveal the function of Tat-SAG in the SH-SY5Y cells.

Furthermore, our *in vivo* study revealed that Tat-SAG has the capability to cross the BBB and, through just a single administration of Tat-SAG, protects DA neurons in the SN against MPTP toxicity, subsequently maintaining the motor functions in the Tat-SAG-treated mice ([Fig. 5](#f5-molcell-37-3-226-6){ref-type="fig"}). In this regard, we clearly showed that the increase of cellular levels of SAG enhances the cellular viability of the SH-SY5Y neuroblastoma cell line and DA neurons in the SN. Also, we previously reported that Tat-SAG significantly protects astrocyte cells and the CA1 region in the hippocampus of gerbil brains from ischemic damage ([@b15-molcell-37-3-226-6]).

The BBB is known as an obstacle to the delivery of therapeutic molecules to brain. It is therefore noteworthy that Tat-SAG, which has the capability to reduce oxidative stress-induced toxicity, could be effectively and easily delivered to cells and brain tissues, as shown in several studies including our data. On the other hand, we identified that PTD fusion proteins, including PEP-1-rpS3 and Tat-frataxin, are retained in cells and tissues for a considerable period and then gradually disappear (unpublished data). These results seem to demonstrate another advantage of PTD fusion proteins. Continuous overexpression in some cells and tissues could render excessive growth-promoting conditions to normal cells and tissues, thereby likely causing side effects. Consequently, our present study is considered as another promising observation showing that PTD-fusion proteins could provide appropriate therapeutic agents against diseases such as PD.

In conclusion, the present study demonstrates that Tat-SAG can cross cellular membranes and the BBB, and suppress ROS generation, DNA damage, and cell death induced by oxidative stress and consequently protect DA neurons in the SN in a PD animal model. Taken collectively, it is likely that Tat-SAG could be a promising agent against ROS-related diseases such as inflammation and PD.
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![Overexpression and purification of Tat-SAG protein. (A) Schematic structure of SAG and Tat-SAG. The His sequence was used for purification and detection of both SAG and Tat-SAG in Western blot analysis. (B) SDS-PAGE and (C) Western blot analysis of purified SAG and Tat-SAG. Overexpressed SAG and Tat-SAG proteins were purified using Ni^2+^-nitrilotriacetic acid Sepharose column. The purified SAG and Tat-SAG were analyzed by 15% SDS-PAGE, electrotransferred to nitrocellulose membrane, and probed with an anti-His and secondary antibody. Lane M, molecular weight marker (EBM-1035, Elpisbiotech, Korea); lane 1, SAG; lane 2, Tat-SAG.](molcell-37-3-226-6f1){#f1-molcell-37-3-226-6}

![*In vitro* transduction of Tat-SAG into SH-SY5Y cells. (A) To assess the dose-dependency of transduction of SAG and Tat-SAG, SH-SY5Y cells were incubated with various concentrations of SAG and Tat-SAG (0.5--3.0 μM) for 60 min. (B) To assess a time-dependency of transduction of SAG and Tat-SAG, SH-SY5Y cells were incubated with SAG and Tat-SAG (3.0 μM) for various time periods (10--60 min). The cells were treated with EDTA-trypsin for 10 min, washed with PBS three times, and harvested by centrifugation. Transduced SAG and Tat-SAG in cell extracts were identified by SDS-PAGE and Western blot analysis using a histidine and a horseradish peroxidase-conjugated secondary antibody. Cellular level of each protein was quantified using a densitometer and bar graph represents the β-actin normalized data. (C) Fluorescence microscopic data showing a transduction of SAG and Tat-SAG into SH-SY5Y cells. Cells were exposed to SAG and Tat-SAG (3 μM) for 60 min and two proteins were probed with a rabbit anti-histidine and Alexa fluor 488-conjugated anti-rabbit secondary antibody. (D) Intracellular stability of transduced Tat-SAG. Purified Tat-SAG (3 μM) was transduced into cells for 60 min and the intracellular level of exogenous Tat-SAG was measured by Western blot analysis for 60 h. The bar graph represents means ± SD from three independent experiments. Arb. unit, arbitrary unit.](molcell-37-3-226-6f2){#f2-molcell-37-3-226-6}

![Effect of Tat-SAG on MPP^+^-induced ROS generation and cell death. (A) Effect of SAG and Tat-SAG on MPP^+^-induced ROS generation in SH-SY5Y cells. SAG and Tat-SAG were transduced into SH-SY5Y cells prior to MPP^+^ treatment (4.0 mM) for 30 min. The cells were exposed to a fluorescent dye, DCF-DA, and then observed by fluorescent microscopy. Ph image, Phase contrast image. (B) Effects of SAG and Tat-SAG on MPP^+^-induced toxicity in SH-SY5Y cells. Cells were preincubated with SAG and Tat-SAG (0.1--0.5 μM) and cellular toxicity was induced by MPP^+^ (4.0 mM) for 18 h. Cell viability was assessed using an MTT assay. Effects of SAG and Tat-SAG on SH-SY5Y cell survival were compared in the presence or absence of MPP^+^. The bar graph represents means ± SD from three independent experiments. Data were analyzed by Student's *t*-test. \**P* \< 0.05 and \*\**P* \< 0.01 indicate a statistically significant difference between MPP^+^-treated control and Tat-SAG-treated samples.](molcell-37-3-226-6f3){#f3-molcell-37-3-226-6}

![Tat-SAG inhibits MPP^+^-induced apoptosis in SH-SY5Y cells. SH-SY5Y cells were incubated with Tat, SAG, or Tat-SAG (0.3 μM) for 60 min, followed by treatment with MPP^+^ (4.0 mM) for additional 18 h. (A) A level of damaged DNA and (B) a fluorescent level of each sample was quantified by TUNEL assay. \**P* \< 0.05 and \*\**P* \< 0.01 for MPP^+^ versus other groups. (C, D) Effect of Tat-SAG on the levels of pro- or anti-apoptotic markers. Levels of caspase-3, cleaved caspase-3, Bcl-2, and Bax were evaluated using (C) Western blot analysis and (D) were quantified using a densitometer. The following antibodies were used; mouse anti-caspase-3, mouse anti-cleaved caspase-3, mouse anti-bcl-2, mouse anti-bax, and mouse anti-β-actin. Western blotting analysis was independently repeated three times. Data were analyzed by Student's *t*-test. \**P*. \< 0.05 and \*\**P* \< 0.001 indicate a statistically significant difference between MPP^+^-treated group and other groups.](molcell-37-3-226-6f4){#f4-molcell-37-3-226-6}

![Tat-SAG protects DA neurons in the SN against MPTP toxicity in the MPTP-induced PD model. (A) Photomicrographs showing transduction of Tat-SAG into the SN. The brains were taken at 12 h after injection of SAG and Tat-SAG at a dose of 3 mg/ kg body weight per mouse (n = 7 mice/group) and immunostained with a rabbit anti-histidine antibody and biotinylated goat anti-rabbit secondary antibody. Lower panels, images with high magnification. (B) Protective effect of Tat-SAG on MPTP-induced cell death of DA neurons in the SN. Left panel, stained with an anti-TH antibody against DA neurons; right panel, double-stained with a TH antibody and cresyl violet for Nissl bodies. The shown images are representatives from each group. Scale bars, 100 μm for (A, B); 50 μm for high magnifications in (A, B). (C) The number of TH positive DA neurons in the SN. Quantification of the number of DA neurons in 250 × 250 μm^2^ (n = 7 mice/group) is shown in the graph. (D-E) Effect of Tat-SAG on the behavior of mice in a MPTP-induced PD model. Each mouse was placed on a Rotarod. (D) The distance and (E) the time that the mice stayed on a Rotarod without falling were recorded. All groups are as follows; CTL, untreated control; MPTP, MPTP-treated group; Tat-SAG, Tat-SAG and MPTP-treated group; SAG, SAG and MPTP-treated group; Tat, Tat and MPTP-treated group. \*\**P* \< 0.001 for MPTP versus other groups; ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.005, and ^\#\#\#^*P* \< 0.001 for control versus other groups.](molcell-37-3-226-6f5){#f5-molcell-37-3-226-6}
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